New Companies
Filter News
Found 4,243 articles
-
Zylö announces the creation and spinout of Atticus Pharma Inc.
4/17/2024
Zylö recently effected a spinout of Atticus Pharma Inc., whose mission is to unlock the value of the Z-pod ® topical delivery platform in the pharmaceutical vertical.
-
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
4/11/2024
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.
-
A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.
-
The Cambridge-based biotech was co-founded by Atlas Ventures and CEO Alex Lugovsky to develop agonist antibodies for rare diseases, with a lead program in hereditary hemorrhagic telangiectasia.
-
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
4/3/2024
Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
-
3M Completes Spin-off of Solventum
4/1/2024
3M completed the planned spin-off of its health care business, which formally launches Solventum Corporation as an independent company.
-
ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR
3/25/2024
ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC).
-
Mirador Therapeutics emerged from stealth Thursday with financing from ARCH Venture Partners and Sanofi, among others, to provide precision medicines for inflammatory and fibrotic diseases.
-
Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases
3/21/2024
Mirador Therapeutics, Inc. (Mirador) announced its launch today.
-
Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity
3/20/2024
Clasp Therapeutics launched today with $150 million in financing.
-
YourChoice Therapeutics Scientific Advisory Board member updates phase 1a study for male birth control candidate at ACS Spring 24
3/19/2024
YourChoice Therapeutics, a San Francisco biotech startup developing the first hormone-free male birth control pill, announced today that Gunda Georg, YCT-529’s co-inventor, provided an update on its phase 1a clinical study for the first hormone-free male birth control pill, YCT-529, at the American Chemical Society (ACS) 2024 Spring Meeting.
-
Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis
3/14/2024
Gynica, a clinical-stage women's health biotech startup developing a novel Endometriosis treatment, announces today the submission of a first-in-human Phase 1 trial.
-
Alkermes spun off its oncology business in late 2023 to become a pure-play neuroscience company, while Jazz Pharmaceuticals continues to invest in and focus on both of its businesses.
-
3M Board of Directors Approves Spin-off of Solventum
3/8/2024
3M announced that its Board of Directors has approved the planned spin-off of its Health Care business, which will be known as Solventum Corporation.
-
Enlyte and Former Genex Leaders Reach Agreement to Create New IME Business
3/5/2024
Enlyte and its Board of Directors have made the strategic decision to transfer its Independent Medical Examination (IME) business and more than 350 employees from Enlyte to the creation of a new, stand-alone IME company, Emperion, Inc.
-
Formerly known as Ryne Bio, Kenai Therapeutics emerged on Thursday with backing from several groups and has a cell therapy candidate going after Parkinson’s disease.
-
Denmark-based startup Orbis Medicines has launched with €26 million in seed funding in its drive to search for macrocycle drugs, with a focus on high-value oral alternatives to blockbuster biologics.
-
3M Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Health Care Business as Solventum
2/21/2024
3M announced the filing of a Form 10 registration statement with the U.S. Securities and Exchange Commission for the planned spin-off of its Health Care business as the newly independent health care company Solventum.
-
Odne Inc. Welcomes Jeff Durrbeck as President of US Operations
2/21/2024
Odne Inc. is thrilled to announce the appointment of Jeff Durrbeck as the President of US Operations.
-
Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)
2/20/2024
Prolocor, Inc. today announced the acceptance of its abstract titled ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTION at The American College of Cardiology (ACC) Scientific Sessions 2024 in Atlanta.